UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies

Frontiers in immunology, 2021-09, Vol.12, p.737311-737311

2021

Volltextzugriff (PDF)

Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status

British journal of cancer, 2020-09, Vol.123 (5), p.752-761

2020

Volltextzugriff (PDF)

Co-Targeting the EGFR and PI3K/Akt Pathway to Overcome Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma: What about Autophagy?

Cancers, 2022-12, Vol.14 (24), p.6128

2022

Volltextzugriff (PDF)

The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy

Frontiers in oncology, 2021-09, Vol.11, p.697967-697967

2021

Volltextzugriff (PDF)

The prognostic impact of the immune signature in head and neck squamous cell carcinoma

Frontiers in immunology, 2022-10, Vol.13, p.1001161-1001161

2022

Volltextzugriff (PDF)

Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines

Molecular oncology, 2018-06, Vol.12 (6), p.830-854

2018

Volltextzugriff (PDF)

Editorial: Advances in the Pathogenesis and Therapeutic Strategies for Nasopharyngeal Carcinoma

Frontiers in oncology, 2021-03, Vol.11, p.647809-647809

2021

Volltextzugriff (PDF)

In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53

Molecular oncology, 2019-05, Vol.13 (5), p.1196-1213

2019

Volltextzugriff (PDF)

Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib

Cancers, 2019-01, Vol.11 (1), p.98

2019

Volltextzugriff (PDF)

Feasibility of tongue strength measurements during (chemo)radiotherapy in head and neck cancer patients

Supportive care in cancer, 2017-11, Vol.25 (11), p.3417-3423

2017

Volltextzugriff (PDF)

Platinum-based chemotherapy (CT) plus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck cancer (R/M-SCCHN): 5-year follow-up data for the extreme trial

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.6021-6021

2014

Volltextzugriff (PDF)

Treatment of Elderly Patients with Squamous Cell Carcinoma of the Head and Neck

Frontiers in oncology, 2016-08, Vol.6, p.199-199

2016

Volltextzugriff (PDF)

Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR‐targeting agents to treat head and neck squamous cell carcinoma

Medicinal research reviews, 2022-01, Vol.42 (1), p.112-155

2022

Volltextzugriff (PDF)

Human papillomavirus-related head and neck tumors: clinical and research implication

Current opinion in oncology, 2009-05, Vol.21 (3), p.201-205

2009

Volltextzugriff (PDF)

Abstract 3371: Role of the epidermal growth factor receptor expression and internalization in cetuximab-induced antibody-dependent cellular cytotoxicity in head and neck squamous cell carcinoma

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.3371-3371

2020

Volltextzugriff (PDF)

Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994

Journal of clinical oncology, 2023-11, Vol.41 (32), p.5035-5043

2023

Volltextzugriff (PDF)

Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck Cancer

Clinical therapeutics, 2019-12, Vol.41 (12), p.2517-2528.e28

2019

Volltextzugriff (PDF)

A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS6090-TPS6090

2018

Volltextzugriff (PDF)

Larynx preservation clinical trial design: Key issues and recommendations-A consensus panel summary

Head & neck, 2009-04, Vol.31 (4), p.429-441

2009

Volltextzugriff (PDF)

Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status

Cancers, 2019-11, Vol.11 (12), p.1893

2019

Volltextzugriff (PDF)

Simultaneous targeting of EGFR , HER 2, and HER 4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines

Molecular oncology, 2018-06, Vol.12 (6), p.830-854

2018

Volltextzugriff (PDF)

LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.6001-6001

2017

Volltextzugriff (PDF)

Biologic Therapy in Head and Neck Cancer : A Road with Hurdles

ISRN oncology, 2012, Vol.2012 (2012), p.1-15

2012

Volltextzugriff (PDF)

Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity

Cancer drug resistance, 2023-01, Vol.6 (4), p.709-28

2023

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(37)
Bücher
(2)

Sprache

Englisch
(39)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(23)
Science & Technology
(23)
Oncology
(18)
Humans
(11)
Chemotherapy
(8)
Cetuximab
(7)
Head & Neck Cancer
(7)
Cancer
(5)
Cancer Therapies
(5)
Head And Neck Cancer
(5)
Human Papillomavirus
(5)
Hypoxia
(5)
Immunotherapy
(5)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Apoptosis
(4)
Cell Cycle
(4)
Cell Death
(4)
Cytotoxicity
(4)
Egfr
(4)
Epidermal Growth Factor
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies

Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status

Co-Targeting the EGFR and PI3K/Akt Pathway to Overcome Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma: What about Autophagy?

The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy

The prognostic impact of the immune signature in head and neck squamous cell carcinoma

Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines

Editorial: Advances in the Pathogenesis and Therapeutic Strategies for Nasopharyngeal Carcinoma

In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53

Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib

Feasibility of tongue strength measurements during (chemo)radiotherapy in head and neck cancer patients

Platinum-based chemotherapy (CT) plus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck cancer (R/M-SCCHN): 5-year follow-up data for the extreme trial

Treatment of Elderly Patients with Squamous Cell Carcinoma of the Head and Neck

Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR‐targeting agents to treat head and neck squamous cell carcinoma

Human papillomavirus-related head and neck tumors: clinical and research implication

Abstract 3371: Role of the epidermal growth factor receptor expression and internalization in cetuximab-induced antibody-dependent cellular cytotoxicity in head and neck squamous cell carcinoma

Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994

Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck Cancer

A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669

Evolution of self‐perceived swallowing function, tongue strength and swallow‐related quality of life during radiotherapy in head and neck cancer patients

Larynx preservation clinical trial design: Key issues and recommendations-A consensus panel summary

Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status

Simultaneous targeting of EGFR , HER 2, and HER 4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines

LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts)

Biologic Therapy in Head and Neck Cancer : A Road with Hurdles

Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity

Suchergebnisse filtern